Please assess the completion status of the following clinical trial:

Trial Title: Study of Nicotine Patches in Patients With Sarcoidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • Symptomatic (active) granulomatous lung disease (radiographic stage II or III disease) at least 6 months after the diagnosis. This selects patients that have the chronically active variant of sarcoidosis and will likely require long-term treatment (33).~Exclusion Criteria:~* • Active smokers,~  * Previous splenectomy,~ * Those requiring high-dose immunosuppression \[i.e., ≥ 0.2 mg/kg/day prednisone (or equivalent) or \> 10 mg/week methotrexate or requires second line cytolytic agents (e.g., cyclophosphamide, azathioprine) or anti-TNF treatments (e.g., thalidomide, anti-TNF antibodies, etc.)\] to control disease activity.~ * We will also exclude patients at high risk of complications relating to the use of nicotine. This will include patients with a known intolerance of nicotine or those with active cardiac or central nervous system disease who are at higher risk of cardiac arrhythmias or seizures.~ * We will also exclude patients with extensive pulmonary fibrosis based upon lung biopsy or high resolution CT scan criterion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2. (Type: NO_INTERVENTION): control group-no intervention
- 3 (Type: NO_INTERVENTION): Healthy control group-blood and sputum samples
- 1. (Type: EXPERIMENTAL): nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).